[May-2026 Newly Released] CCDM Exam Questions For You To Pass
SCDM CCDM Exam: Basic Questions With Answers
NEW QUESTION # 50
A Data Manager receives an audit finding of missing or undocumented training for two database developers according to the organization's training SOP and matrix. Which is the best response to the audit finding?
- A. Remove the training items from the training matrix
- B. Send the two developers to the required training
- C. Identify the root cause and improve the process to prevent it
- D. Reprimand the person responsible for maintaining training documentation
Answer: C
Explanation:
When an audit identifies missing or undocumented training, the most appropriate and compliant response is to identify the root cause of the issue and implement corrective and preventive actions (CAPA) to ensure that similar findings do not recur.
According to Good Clinical Data Management Practices (GCDMP, Chapter: Quality Management and Auditing), effective quality systems require root cause analysis (RCA) for all audit findings. The process involves:
Investigating why the documentation gap occurred (e.g., poor tracking, outdated SOP, or lack of oversight).
Correcting the immediate issue (e.g., ensuring the developers complete or document training).
Updating processes, training systems, or oversight mechanisms to prevent recurrence.
While sending the two developers to training (D) addresses the symptom, it does not resolve the systemic issue identified by the audit. Options B and C are non-compliant and do not address quality system improvement.
Therefore, option A (Identify the root cause and improve the process) is the best and CCDM-compliant response.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Quality Management and Auditing, Section 6.2 - Corrective and Preventive Actions (CAPA) ICH E6(R2) GCP, Section 5.1.1 - Quality Management and Continuous Process Improvement FDA 21 CFR Part 820.100 - Corrective and Preventive Action (CAPA) Requirements
NEW QUESTION # 51
Which of the following is the best reason for a statistician to review the case report form prior to using it in a study?
- A. To ensure the header fields will provide a unique key for each subject
- B. To ensure the layout will make a logical, useful programming guide
- C. To ensure the data from the CRF can be analyzed for safety and efficacy
- D. To ensure the variable names conform to statistical programming standards
Answer: C
Explanation:
The primary reason a statistician reviews the Case Report Form (CRF) is to ensure that the data being collected will support the planned statistical analyses for both safety and efficacy endpoints.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), CRF design should always align with the statistical analysis plan (SAP) to ensure that all necessary data elements are collected accurately and in analyzable formats. The statistician verifies that the CRF captures:
All endpoints specified in the protocol
Proper derivation or calculation fields
Timing of assessments
Consistency across visits and forms
Options B, C, and D address secondary or technical design considerations but not the primary analytical purpose. The review ensures that the CRF provides a complete and analyzable dataset for meeting study objectives, regulatory submissions, and statistical integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.4 - Role of Statistics in CRF Design ICH E9 - Statistical Principles for Clinical Trials, Section 5.2 - Data Collection and Analysis Alignment FDA Guidance for Industry: E6(R2) GCP, Section 5.1 - Quality Management and Design Input from Stakeholders
NEW QUESTION # 52
A study has an expected enrollment period of one year but has subject recruitment issues. Twelve new sites are added toward the end of the expected enrollment period to help boost enrollment. What is the most likely impact on data flow?
- A. The distribution of subjects selected for quality control will need to be stratified to allow for the twelve new sites.
- B. Additional sites will likely have increased query rates since site training is occurring closer to study close.
- C. A bolus of CRFs at the end of the study will result in the need to increase data entry and cleaning rates to meet existing timelines.
- D. The database set-up will need to be changed to allow for additional sites as they are added to the study.
Answer: C
Explanation:
Adding multiple new sites late in the enrollment period creates a concentrated influx of new data near the end of the study. These sites typically start enrolling patients later, resulting in a "bolus" of Case Report Forms (CRFs) that must be entered, validated, and cleaned within a shorter timeframe to meet database lock deadlines.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Data Flow), late site activation compresses the timeline for data management tasks, necessitating increased resources for data entry, query management, and cleaning. Data management teams must anticipate this surge and plan accordingly-either by increasing staffing or revising timelines to prevent bottlenecks and maintain quality.
While option D (increased query rates) can occur, it is a secondary effect. The most direct and consistent impact is the surge in data volume requiring expedited processing near study end.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 5.3 - Managing Changes in Site Activation and Data Flow ICH E6(R2) GCP, Section 5.1 - Quality Management and Oversight
NEW QUESTION # 53
Which information is required by most systems to specify data entry screens?
- A. Page number and total number of pages
- B. Help text, review parameters, and answers
- C. Data type, prompt, and response format
- D. User role, access level, and permissions
Answer: C
Explanation:
When designing or configuring data entry screens within an Electronic Data Capture (EDC) system, three critical components are required for each field:
Data Type - Defines the nature of the data (e.g., text, numeric, date).
Prompt - The label or question displayed to the user.
Response Format - Specifies how the user enters or selects data (e.g., free text, drop-down, checkbox).
According to the GCDMP (Chapter: EDC Systems and Database Design), these three attributes form the logical data structure required to build and validate data entry interfaces. They ensure consistency in how information is captured, displayed, and validated during data entry.
While user roles (A) and help text (D) are system-level configurations, not field-level specifications, page numbers (C) relate to printed CRFs rather than digital data screens.
Therefore, option B (Data type, prompt, and response format) correctly identifies the essential information needed to define data entry screens.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: EDC Systems and Database Design, Section 4.3 - Screen Design Specifications CDISC CDASH Implementation Guide, Section 3.2 - Data Field Attributes ICH E6(R2) GCP, Section 5.5.3 - Data Capture and Input Standards
NEW QUESTION # 54
What method is used for quality control of the query resolution process?
- A. Perform random audits of the resolved query forms.
- B. Tabulate the number of queries sent per site.
- C. Calculate the time from query sent to query resolution from the site.
- D. Calculate the time from discrepancy identified to query sent.
Answer: A
Explanation:
The most effective method for quality control (QC) of the query resolution process is to perform random audits of resolved query forms. This ensures that queries are being appropriately raised, addressed, and resolved in accordance with the study protocol, data management plan (DMP), and standard operating procedures (SOPs).
According to the GCDMP (Chapter: Data Validation and Cleaning), QC activities should verify that the data review and query management process maintains high accuracy and consistency. Random auditing of resolved queries enables verification that:
Queries were raised for legitimate discrepancies,
The site's responses were appropriate, and
The resolution actions taken by data management were correct and well-documented.
Metrics such as turnaround time (options A and C) or query counts (option B) measure efficiency but do not assess quality. True quality control focuses on ensuring that data corrections preserve accuracy, auditability, and traceability - the fundamental principles of data integrity in clinical research.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.4 - Query Management and Quality Control ICH E6 (R2) GCP, Section 5.5.3 - Data Integrity and Validation Procedures
NEW QUESTION # 55
A Data Manager receives an audit finding of three different instances of simultaneous log-ins to the EDC system by the same site user. This was observed at three different sites. Which of the following is the best long-term response to the audit finding?
- A. Requesting that the sites fire the offending users for a HIPAA violation and increasing the monitoring for the offending sites
- B. Removing all access to the system until the situation is resolved
- C. Acquiring technical controls from the same or a different system vendor that prevent simultaneous log-ins from the same user
- D. Refresher training for the offending users, re-communication of the binding nature of e-signatures to all users, routine monitoring for simultaneous log-ins from the same user
Answer: D
Explanation:
The best long-term corrective and preventive action (CAPA) in this situation is a combination of user re-training, communication, and routine monitoring - as described in Option B.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, user credentials and electronic signatures in clinical systems are legally binding and must be used only by the assigned individual. Simultaneous log-ins under the same credentials often indicate credential sharing, a compliance violation that must be addressed through user education, reinforced security policies, and ongoing system oversight.
While technical controls (option A) may be considered, behavioral and procedural reinforcement are the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 7.1 - User Access, Authentication, and Training FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Access Control and Audit Trail Requirements
NEW QUESTION # 56
Before the EDC system used for the trial is upgraded, what should be the data manager's first task?
- A. Update the user manual
- B. Redesign the eCRF
- C. Notify the sites of the upgrade
- D. Assess the impact on the data
Answer: D
Explanation:
Before implementing an EDC system upgrade, the first task of the Data Manager is to assess the impact on the data.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, any system upgrade must undergo impact assessment to determine how the change might affect data integrity, functionality, validation, and ongoing study operations. This assessment ensures that no data are lost, corrupted, or rendered inconsistent during or after the upgrade.
The Data Manager should evaluate:
Potential effects on existing data, edit checks, and reports,
System functionality impacting current workflows, and
Any revalidation requirements.
Only after the impact is understood should the Data Manager proceed to communicate with sites (option A), update documentation (option B), or modify CRFs if required (option D).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture Systems, Section 7.3 - System Upgrades and Change Control FDA 21 CFR Part 11 - Change Control and Validation Requirements ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Change Impact on Data Integrity and System Validation
NEW QUESTION # 57
Which of the following laboratory findings is a valid adverse event reported term that facilitates auto coding?
- A. Increased alkaline phosphatase, increased SGPT, increased SGOT, and elevated LDH
- B. Abnormal SGOT
- C. ALT
- D. Elevated HDL
Answer: D
Explanation:
When coding adverse events (AEs) using MedDRA (Medical Dictionary for Regulatory Activities), valid AE terms must correspond to specific, medically meaningful concepts that match directly to a Preferred Term (PT) or Lowest Level Term (LLT) in the dictionary.
Among the options, "Elevated HDL" (High-Density Lipoprotein) represents a single, medically interpretable, and standard term that can directly match to a MedDRA LLT or PT. This makes it suitable for auto-coding, where the system automatically maps verbatim terms to MedDRA entries without manual intervention.
In contrast:
ALT (B) and Abnormal SGOT (C) are incomplete or nonspecific; they describe test names or qualitative interpretations rather than events.
Option D lists multiple findings, making it too complex for automatic mapping. Such compound entries would require manual coding review.
According to GCDMP (Chapter: Medical Coding and Dictionaries), a valid AE term should be:
Clinically interpretable (not just a lab test name)
Unambiguous
Single-concept based, not a collection of results
Thus, option A (Elevated HDL) is correct, as it aligns with MedDRA's single-concept, standard terminology structure suitable for auto-coding.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.3 - Auto-coding and Verbatim Term Management ICH M1 MedDRA Term Selection: Points to Consider, Section 2.1 - Coding Principles ICH E2B(R3) - Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
NEW QUESTION # 58
Which is the most important reason for why a data manager would review data before a monitor reviews it?
- A. Data managers write the Data Management Plan that specifies the data cleaning workflow.
- B. Data can be viewed and discrepancies highlighted prior to a monitor's review.
- C. The GCDMP recommends that data managers review data prior to a monitor's review.
- D. Data managers have access to programming tools to identify discrepancies.
Answer: B
Explanation:
The primary reason data managers review data before a monitor's review is to identify and flag discrepancies or inconsistencies so that site monitors can focus their efforts more efficiently during on-site or remote source data verification (SDV).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), proactive data review by data management staff ensures data completeness and accuracy by identifying missing, inconsistent, or out-of-range values. This pre-review helps streamline the monitoring process, reduces the volume of open queries, and enhances data quality.
Option A is true but not the main reason for pre-monitor review. Option C highlights a capability rather than a rationale. Option D is partially correct, but the GCDMP emphasizes process purpose, not prescriptive order. Thus, option B correctly captures the practical and process-oriented reason for early data review-to ensure data are ready and accurate for the monitor's review phase.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.3 - Data Review Timing and Purpose ICH E6(R2) GCP, Section 5.18 - Monitoring and Data Verification Requirements
NEW QUESTION # 59
An astute monitor discovers that a site is using nebulized albuterol rather than the inhaler provided in the study screening kit for the albuterol challenge. Which is the best response from the Data Manager?
- A. Contact the Ethics Committee
- B. Query the site to enter a Protocol Violation
- C. Update the CRF Completion Guidelines and notify all sites of the update
- D. No response is needed, the problem does not impact data
Answer: B
Explanation:
In this scenario, the site has deviated from the approved study protocol by using a different formulation (nebulized albuterol instead of inhaler). This is considered a protocol deviation or violation, depending on study definitions.
Per GCDMP (Chapter: Data Validation and Cleaning) and ICH E6(R2), Data Managers are responsible for ensuring that all protocol deviations affecting data integrity or subject safety are accurately captured and documented within the clinical database. The appropriate action is to issue a data query prompting the site to record the deviation in the designated section (e.g., "Protocol Deviations" CRF).
Option A: Incorrect - it affects data comparability.
Option B: Escalation to the Ethics Committee is handled by the sponsor, not the Data Manager.
Option C: Updating the CRF guidelines is premature; first, the deviation must be logged and assessed.
Therefore, option D (Query the site to enter a Protocol Violation) is the correct and compliant action.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Query Management and Protocol Deviations ICH E6(R2) GCP, Section 4.5 - Compliance with Protocol FDA Guidance for Industry: Oversight of Clinical Investigations - Compliance and Protocol Deviation Reporting
NEW QUESTION # 60
What does 21 CFR Part 11 dictate in regards to a minimum expectation of EDC training prior to access?
- A. Training must be face to face
- B. Training must include an exam
- C. Training must be in the user's native language
- D. Training must be performed
Answer: D
Explanation:
Under FDA 21 CFR Part 11, organizations using electronic systems must ensure that all system users are trained to perform their assigned functions before gaining access to the system. The regulation requires documented evidence of training but does not specify how it should be conducted (e.g., exam-based, in person, or language-specific).
The GCDMP (Chapter: Computerized Systems and Compliance) further clarifies that personnel training should include instruction on system functionality, audit trails, data entry procedures, and electronic signatures to maintain compliance and data integrity. Training must be performed and documented but does not require a specific format or delivery method.
Therefore, option A-Training must be performed-is correct, as it reflects the minimum regulatory expectation per FDA and SCDM standards.
Reference (CCDM-Verified Sources):
FDA 21 CFR Part 11, Section 11.10(i) - Personnel Training Requirements
SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.4 - System Training and Documentation ICH E6(R2) GCP, Section 2.8 - Qualified Personnel and Training Requirements
NEW QUESTION # 61
A site study coordinator attempts to make an update in a study database in an EDC system after lock. What occurs?
- A. The site study coordinator is not able to make the change
- B. The change is logged as occurring after lock
- C. The old value is replaced in all locations by the new value
- D. The change is approved by the Data Manager before it is applied
Answer: A
Explanation:
Once a clinical database is locked, it becomes read-only - no further data modifications can be made by any users, including site personnel. This ensures that the data are finalized, consistent, and auditable for statistical analysis and regulatory submission.
According to the GCDMP (Chapter: Database Lock and Archiving), the lock process involves freezing the database to prevent accidental or unauthorized changes. After lock, access permissions are restricted, and all edit and update functions are disabled. If any corrections are required post-lock, the database must be unlocked under controlled procedures (with full audit trail documentation).
Thus, option C - The site study coordinator is not able to make the change - correctly reflects standard EDC functionality and regulatory compliance.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.2 - Database Lock Procedures and Controls ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Audit Trail Requirements FDA 21 CFR Part 11 - Controls for Electronic Records and System Lock Functions
NEW QUESTION # 62
When a data manager runs a report on resolution types of discrepancy status, which of the following would NOT be a part of resolution types?
- A. Resolved with data/confirmed as is (non problematic)
- B. Cannot be resolved (but data incorrect)
- C. Received from site and not yet reviewed
- D. Data management - self evident corrections
Answer: C
Explanation:
In a discrepancy management workflow, "Received from site and not yet reviewed" is not a resolution type - it represents a status, not a final resolution outcome.
According to the GCDMP (Chapter: Data Validation and Cleaning), resolution types describe how a data discrepancy was finalized or addressed, such as:
Resolved with data correction,
Confirmed as correct (no change required),
Self-evident correction applied by data management, or
Unresolvable discrepancies documented.
In contrast, statuses describe the stage of the query (e.g., open, sent, answered, pending review, closed). "Received from site and not yet reviewed" indicates an intermediate workflow state where the response awaits validation by data management.
Proper classification of resolution types is essential for performance reporting, audit readiness, and ensuring the traceability of query management actions under ICH E6 (R2) and FDA 21 CFR Part 11.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.3 - Discrepancy Resolution Lifecycle ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Handling and Record Management FDA 21 CFR Part 11 - Electronic Records; Audit Trails and Discrepancy Tracking Requirements
NEW QUESTION # 63
In reviewing the adverse events for a subject, a data manager notices one recorded as "worsening of migraine." After reviewing the rest of the adverse events and finding no other migraine recordings, what is the data manager's next step?
- A. Query the site for more information on the adverse event, "worsening of migraine."
- B. Look for any adverse event instance of headache and assume the events are similar.
- C. Check the medical history for recording of a history of migraines.
- D. Query the site for the first adverse event occurrence of migraine.
Answer: A
Explanation:
When a data inconsistency arises - such as a record of "worsening of migraine" without prior documentation of a migraine episode - the Data Manager should query the site for clarification (Option D).
According to the GCDMP (Chapter: Data Validation and Cleaning), data managers must raise a clarification query whenever data appear incomplete, inconsistent, or ambiguous. The site must confirm whether "worsening of migraine" refers to a new event or an exacerbation of a preexisting condition. This clarification ensures accurate safety reporting and appropriate medical coding (e.g., MedDRA classification).
Checking the medical history (Option C) may help but does not resolve the inconsistency. Assuming a relationship (Option A or B) without verification would violate Good Clinical Data Management Practice and potentially misrepresent the adverse event.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Query Generation and Resolution ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Section II - Data Clarification Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Query Management
NEW QUESTION # 64
To ensure data quality and efficient integration of data, which of the following best describes the main topic that should be covered in initial discussions with a vendor providing the external data?
- A. Acceptable record, field, and file formats
- B. Metrics that will be used to measure data quality
- C. Standard dictionary versioning and maintenance
- D. Criteria to trigger audits based on performance-monitoring reports
Answer: A
Explanation:
In initial vendor discussions for external data integration (e.g., central lab, ECG, imaging vendors), the most critical and foundational topic is defining the acceptable record, field, and file formats.
According to the GCDMP (Chapter: External Data Transfers and Integration), establishing the Data Transfer Specifications (DTS) early in the process ensures consistent structure, proper mapping, and compatibility between the vendor's system and the sponsor's database. These specifications define:
Data structure (variable names, formats, delimiters)
File naming conventions
Frequency of transfers
Methods of secure data transmission
Discussing formats first allows later alignment on data validation, quality metrics, and dictionary standards (which occur in subsequent stages). Without format agreement, all downstream processes risk misalignment, resulting in data incompatibility and rework.
Thus, option C (Acceptable record, field, and file formats) correctly represents the foundational focus of initial vendor discussions for ensuring data quality and integration efficiency.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 4.1 - Data Transfer Planning and Specification Development ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Validation FDA Guidance: Computerized Systems Used in Clinical Investigations, Section 6.3 - Data Import and Format Control
NEW QUESTION # 65
A study team member wants to let sites enroll patients before the system is ready. Which are important considerations?
- A. Starting the study prior to the EDC system being ready will delay processing of milestone-based site payments
- B. If the study were audited, enrolling subjects prior to having the EDC system ready would become an audit finding
- C. Without the ability to capture the data electronically, the data cannot be checked or used to monitor and manage the study
- D. There is no way to identify, report and track adverse events and serious adverse events without the EDC system in place
Answer: C
Explanation:
Enrolling subjects before the Electronic Data Capture (EDC) system is ready poses major data integrity and compliance risks. The primary issue is that data cannot be accurately captured, validated, or monitored without the system in place.
Per the GCDMP (Chapter: Data Management Planning and Study Start-up), data collection systems must be fully validated, tested, and released before enrollment begins to ensure:
Real-time data entry and quality control
Proper tracking of adverse events (AEs/SAEs)
Audit trails and traceability for regulatory compliance
Option A highlights the most critical consequence - without an operational EDC, data collection and verification processes cannot occur, compromising data quality and study oversight.
While options B, C, and D may be partially true, they are secondary effects. The fundamental consideration is data capture capability and monitoring control, making option A correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Management Planning and Study Start-up, Section 4.2 - EDC Readiness and System Validation ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation Before Use FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - System Qualification Prior to Data Entry
NEW QUESTION # 66
A study is collecting ePRO assessments as well as activity-monitoring data from a wearable device. Which data should be collected from the ePRO and activity-monitoring devices to synchronize the device data with the visit data entered by the site?
- A. Geo-spatial location and study subject identifier
- B. Study subject identifier and date/time
- C. Geo-spatial location
- D. Study subject identifier
Answer: B
Explanation:
To synchronize data from electronic patient-reported outcomes (ePRO) and wearable activity-monitoring devices with site-entered visit data, both the study subject identifier and date/time are essential.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), each dataset must contain key identifiers that allow for accurate data integration and temporal alignment. In studies involving multiple digital data sources, time-stamped subject identifiers are necessary to ensure that the device-generated data correspond to the correct subject and study visit.
The subject identifier ensures data traceability and linkage to the appropriate participant, while date/time allows synchronization of device data (e.g., activity or physiological measurements) with the corresponding site-reported visit or event. Geo-spatial data (options C and D) are typically not relevant to study endpoints and pose unnecessary privacy risks under HIPAA and GDPR guidelines.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Integration and eSource Data, Section 5.2 - Data Alignment and Synchronization Principles FDA Guidance for Industry: Use of Electronic Health Record Data in Clinical Investigations, Section 4.2 - Data Linking and Synchronization ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability and Integrity
NEW QUESTION # 67
Which attribute is NOT a characteristic of a standardized data collection element?
- A. A standard set of values used to respond to a data collection question
- B. A unique set of data storage metadata, including a variable name and data type
- C. An unambiguous definition for the data element
- D. A strictly enforced requirement for the positioning of each data element on a case report form
Answer: D
Explanation:
A standardized data collection element has well-defined metadata, consistent naming conventions, and controlled terminology to ensure uniform data collection and interoperability across studies.
Key attributes, as per GCDMP and CDISC standards, include:
A clear definition of meaning (A)
A controlled set of response values (C)
Metadata specifications like variable names, formats, and data types (D) However, the physical positioning of a data element on a case report form (B) is a matter of form layout design, not a characteristic of data standardization. While consistent form structure aids usability, it is not part of data standardization or metadata management principles.
Hence, option B is correct - form positioning is not a standardized data element attribute.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Standards and Data Integration, Section 4.1 - Data Element Standardization CDISC CDASH Implementation Guide, Section 3.2 - Standardized Data Collection Elements and Metadata ICH E6(R2) GCP, Section 5.5.3 - Data Handling and Standardization
NEW QUESTION # 68
In a study, data are key entered by one person after which a second person enters the data without knowledge of or seeing the values entered by the first. The second person is notified during entry if an entered value differs from first entry and the second person's decision is retained as the correct value. Which type of entry is being used?
- A. Manual review
- B. Blind verification
- C. Single entry
- D. Third-party compare
Answer: B
Explanation:
The described process is Blind Verification, also known as double data entry with blind verification. In this method, two independent operators enter the same data. The second operator is blinded to the first entry to avoid bias. When discrepancies arise, the system flags them for review, and the second entry (or an adjudicated value) is retained as the correct one.
According to GCDMP (Chapter: Data Entry and Data Tracking), blind double data entry is used primarily in paper-based studies to minimize transcription errors and ensure data accuracy.
Single entry (D): Only one operator enters data.
Manual review (B): Involves post-entry checking, not during entry.
Third-party compare (C): Used for reconciling external data sources, not CRF data.
Hence, option A (Blind verification) is the correct and CCDM-defined process.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Entry and Data Tracking, Section 5.1 - Double Data Entry and Verification Methods ICH E6(R2) GCP, Section 5.5.3 - Data Entry and Verification Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Accuracy and Verification
NEW QUESTION # 69
A protocol is updated mid-study to add an additional procedure about which data needs to be collected. Which of these statements applies?
- A. The DMP does not need to be updated as it represents the data at the beginning of the trial only
- B. The DMP does not need to be updated until the end of the trial and all updates are included in the DMP to indicate what happened in the trial
- C. The DMP should be updated to reflect the changes to the protocol, but this update does not need to be communicated
- D. The DMP should be updated to reflect the changes to the protocol and stakeholders notified
Answer: D
Explanation:
When a protocol is amended mid-study, resulting in additional data collection requirements, the Data Management Plan (DMP) must be updated accordingly and all relevant stakeholders must be notified.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the DMP is a living document that defines all data management processes for a clinical study. It must accurately reflect the current data flow, CRF design, validation procedures, and reporting structure. Any protocol amendments affecting data capture, structure, or analysis require immediate DMP revision and distribution to ensure alignment across data management, clinical, and biostatistics teams.
Failure to update and communicate DMP changes can lead to misalignment in data handling and introduce compliance risks during audits or inspections. Therefore, Option B is correct: the DMP must be updated and the change communicated to all stakeholders (e.g., sponsor, CRO, clinical operations, biostatistics).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Plan (DMP), Section 5.3 - Maintaining and Updating the DMP ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Documentation of Protocol Changes and Data Handling Procedures FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Data Management Documentation
NEW QUESTION # 70
A group of researchers is planning an investigator-initiated study. Assuming that SOPs are not available, which is the best approach for documentation of data management in the planned study?
- A. Data management SOPs must be developed prior to initiation of study
- B. A Data Management Plan (DMP) template should be developed and a study DMP should be created
- C. Data management related activities should be briefly described in the study protocol
- D. Data handling should be documented in a data management plan
Answer: B
Explanation:
In the context of an investigator-initiated trial (IIT) where Standard Operating Procedures (SOPs) are not available, the most appropriate and compliant approach is to develop a Data Management Plan (DMP) template and then create a study-specific DMP based on that template (Option C).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Management Planning and Study Start-up), the DMP is the central document that defines all processes, responsibilities, systems, and quality controls related to data collection, processing, validation, and database management throughout the clinical study. The DMP serves as a formal framework for ensuring data integrity, traceability, and regulatory compliance, especially in the absence of established institutional SOPs.
While SOPs provide organizational-level standards, the DMP provides study-specific operational detail. In an investigator-initiated setting, researchers often lack institutional data management infrastructure, so the DMP must substitute for SOP guidance by detailing:
Data entry and validation procedures
Query management and resolution processes
CRF design and data flow specifications
Database design, backup, and security
Responsibilities of study personnel (investigator, data manager, statistician) Quality control and audit trail practices Option A ("Data handling should be documented in a DMP") is correct in principle but incomplete-without a DMP template, there is no standardized format or consistency across studies.
Option B (developing full SOPs) is not practical for a single IIT; SOPs are organizational-level documents requiring longer development and approval cycles.
Option D (briefly describing data management in the protocol) is insufficient, as the protocol should reference data management activities but not serve as the operational manual for them.
Therefore, Option C provides the most comprehensive, regulatory-compliant, and practical solution-ensuring structured documentation of all data management activities while maintaining flexibility for investigator-led research.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 5.2 - Data Management Plan (DMP) Development and Maintenance ICH E6 (R2) Good Clinical Practice, Section 5.1 - Quality Management and Documentation Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 4 - Data Management and Documentation Practices SCDM GCDMP, Chapter: Project Management in Data Management - Study-Specific Documentation and Planning in Investigator-Initiated Trials
NEW QUESTION # 71
The best example of a protocol compliance edit check is:
- A. An edit check that fires when a field is left blank
- B. An edit check that fires when an invalid date is entered
- C. An edit check that fires when a value is outside of the normal range for vital signs
- D. An edit check that fires when a visit date is outside the specified window
Answer: D
Explanation:
A protocol compliance edit check is designed to ensure that the data collected adheres to the specific requirements defined in the study protocol, such as visit timing, procedure windows, and eligibility criteria.
The example in option A - an edit check that triggers when a visit date falls outside the protocol-specified window - directly verifies compliance with the study design. This type of check supports real-time monitoring of protocol adherence, a critical quality and regulatory requirement under GCDMP and ICH E6(R2).
Other options are examples of general data validation checks, not protocol compliance:
B: Ensures clinical plausibility (data range check).
C: Ensures completeness (missing data check).
D: Ensures format correctness (system validation check).
Thus, option A best represents a protocol compliance edit check, confirming that collected data conform to the visit schedule defined in the protocol.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.4 - Protocol Compliance Edit Checks ICH E6(R2) GCP, Section 5.1.1 - Quality Management and Compliance Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - Edit Check Design and Validation
NEW QUESTION # 72
A Data Manager is importing lab data for a study. The lab data and the associated audit trail is kept at the central lab. What is necessary to maintain traceability of the transferred data at the Data Manager's location?
- A. Making changes only on the copy of the received data
- B. Making changes only after data have been imported
- C. Maintaining a copy of the data as received
- D. Making changes only for exceptions
Answer: C
Explanation:
Maintaining traceability of external data imports (such as laboratory results) is a fundamental principle of clinical data management. According to the GCDMP (Chapter: External Data Transfers and Integration), Data Managers must retain an unaltered copy of the raw data exactly as received from the vendor.
This archived version serves as a reference for:
Data provenance verification,
Audit trail review, and
Discrepancy resolution between vendor and study database.
Since the central lab maintains its own audit trail, the Data Manager's responsibility is to preserve the original data transmission file before applying transformations, merges, or validations.
Options A, C, and D describe procedural safeguards but do not meet the regulatory requirement of traceable data lineage. Only option B (Maintaining a copy of the data as received) ensures compliance with ICH E6(R2) and FDA 21 CFR Part 11 standards for data traceability and integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 5.2 - Data Traceability and Version Control ICH E6(R2) GCP, Section 5.5.3 - Data Integrity and Source Data Verification FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 - Source Data Traceability and Archiving
NEW QUESTION # 73
Which statement applies to the CRF Completion Guidelines (CCGs) for a multinational study?
- A. CCGs must be translated and back-translated in each local language used in the study
- B. CCGs can instruct sites to write in their local language as long as the CRA is fluent in this language
- C. CCGs must contain the list of acceptable abbreviations to be used in the CRF
- D. CCGs can instruct sites to use any abbreviations if they are documented in the subject source notes
Answer: C
Explanation:
The Case Report Form (CRF) Completion Guidelines (CCGs) are critical documents that guide site staff on how to accurately and consistently record data on CRFs across all participating sites, especially in multinational trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), one of the key components of the CCGs is a list of acceptable abbreviations and conventions to be used during CRF entry. This standardization ensures data consistency across languages and countries, reduces ambiguity during data review, and facilitates database design and coding accuracy.
While translation (A) may be useful for training materials, it is not required for CCGs unless specified by regulatory bodies. Options C and D are incorrect because data collection should adhere to standardized terms in English (or the study's official language) - allowing free use of local languages or arbitrary abbreviations introduces inconsistencies.
Hence, option B - "CCGs must contain the list of acceptable abbreviations to be used in the CRF" - is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.3 - CRF Completion Guidelines and Standardization ICH E6(R2) GCP, Section 5.5.3 - Consistency and Data Recording Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Entry Conventions and Documentation
NEW QUESTION # 74
A Data Manager is asked to manage SOPs for a department. Given equal availability of the following systems, which of the following is the best choice for managing the organizational SOPs?
- A. Existing paper filing system
- B. Customized Excel spreadsheet
- C. Document management system
- D. Learning management system
Answer: C
Explanation:
The best choice for managing Standard Operating Procedures (SOPs) in a compliant and auditable manner is a Document Management System (DMS).
According to the GCDMP (Chapter: Regulatory Requirements and Compliance) and ICH E6 (R2), SOPs must be version-controlled, securely stored, retrievable, and auditable. A validated DMS supports controlled access, document lifecycle management (draft, review, approval, and archival), and electronic audit trails, ensuring full compliance with FDA 21 CFR Part 11 and Good Documentation Practices (GDP).
While Learning Management Systems (C) track training, they are not intended for document control. Spreadsheets (B) and paper systems (D) cannot provide adequate version tracking, access security, or audit capability required for regulatory inspection readiness.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and Compliance, Section 5.2 - SOP Management and Document Control ICH E6 (R2) GCP, Section 5.5.3 - Document and Record Management FDA 21 CFR Part 11 - Electronic Records and Signatures, Section 11.10 - System Validation and Document Controls
NEW QUESTION # 75
......
New 2026 Realistic Free SCDM CCDM Exam Dump Questions and Answer: https://www.newpassleader.com/SCDM/CCDM-exam-preparation-materials.html
CCDM Practice Test Engine: Try These 152 Exam Questions: https://drive.google.com/open?id=1FLBilqawLpNom_LS2SZlgqmFrzF76iC8